Abstract:OBJECTIVE To investigate the effect of ulinastatin (UTI) on the levels of immune regulatory cells,pro-inflammatory mediators, and the expression of human leukocyte antigen-DR (HLA-DR) in CD14⁺ monocytes. METHODS A total of sixty patients with severe sepsis who were admitted to intensive care unit (ICU) during October 2011 to October 2012 were enrolled. The patients were randomly divided into two groups: routine treatment group (n=30, received routine bundle treatment) and UTI group (n=30, received 30 kU UTI three times per day in addition to routine bundle treatment). A course of treatment consisted of 5 days in both groups. The peripheral blood was collected, and the expression of CD4⁺CD25⁺⁻ regulatory T cell (Treg), help T cell 17 (Th17), interleukin (IL-17, IL-6, IL-10) and HLA-DR were determined before and 5 days after treatment, in order to observe the effect of UTI. RESULTS There was no significant difference in all indexes before treatment between two groups. Compared with routine treatment group, UTI could reduce the abnormal expression of Treg and Th17 in patients with severe sepsis [Treg: (9.05 ± 1.27)% vs. (11.83 ± 1.30)%, Th17:(3.20 ± 0.33)% vs. (4.42 ± 0.35)%, both P<0.01], and decrease the ratio of Treg/Th17 (2.22 ± 0.28 vs. 2.82 ± 0.29, P<0.01) more effectively. UTI could also reduce the abnormal expression of IL-17, IL-6 and IL-10 compared with routine treatment group (IL-17: 98.35 ± 12.23 ng/L vs. 118.20 ± 15.97 ng/L, IL-6: 24.17 ± 6.72 ng/L vs. 29.27 ± 8.13 ng/L, IL-10: 33.17 ± 7.24 ng/L vs. 37.34 ± 8.49 ng/L, P<0.05 or P<0.01). In addition UTI could ameliorate the immune status, improve the expression of HLA-DR compared with routine treatment group [(49.34 ± 11.34)% vs. (36.44 ± 8.14)%, P<0.01]. The 28-day mortality in UTI group showed a tendency of lowering compared with routine treatment group, but the difference between two groups was not significant(18.2% vs. 20.1%, P>0.05). CONCLUSIONS UTI can decrease in the expression of Treg and Th17, inverse the ratio of Treg/Th17, decrease in the expression of IL-17, IL-6 and IL-10, ameliorate the immune status, and improve the expression of HLA-DR. UTI is expected to improve the prognosis of patients with severe sepsis.

Clinical efficacy of ulinastatin in the treatment of unliquefied pyogenic liver abscess complicated by septic shock: A randomized controlled trial

Ulinastatin in the treatment of severe acute pancreatitis: A single-center randomized controlled trial

A retrospective study of the effectiveness of ulinastatin in the treatment of sepsis

Effect of Ulinastatin Combined with Octreotide on Serum Endothelin, Endotoxin Levels and Immune Function in Acute Pancreatitis

Clinical study of ulinastatin on lung injury in patients with septic shock

Early Peritoneal Lavage with Ulinastatin Improves Outcome and Enhances Multi-Organ Protection in a Model of Severe Acute Pancreatitis.

Effects of ulinastatin therapy in emergency severe multiple trauma: A single-center randomized controlled trial

The study of Ulinastatin's curative effect for the patient with sepsis after hepatobiliary surgery

Ulinastatin Enhances the Therapeutic Effect of Intraperitoneal Lavage on Severe Acute Pancreatitis in Rats

A Retrospective Study of Ulinastatin for the Treatment of Severe Sepsis

Effect of Peritoneal Lavage with Ulinastatin on the Expression of NF-κB and TNF-α in Multiple Organs of Rats with Severe Acute Pancreatitis.

Thymosin Alpha(1)- and Ulinastatin-Based Immunomodulatory Strategy for Sepsis Arising from Intra-Abdominal Infection Due to Carbapenem-Resistant Bacteria

Improvement of Sepsis Prognosis by Ulinastatin: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Effect of ulinastatin combined with thymosin alpha1 on sepsis: A systematic review and meta-analysis of Chinese and Indian patients

[The effect of ulinastatin on disbalance of inflammation and immune status in patients with severe sepsis].

Study of ulinastatin against gastrointestinal complications in patients with septic shock

Beneficial effects of ulinastatin on gut barrier function in sepsis

Application of a combination of lactated Ringer's solution and ulinastatin for early resuscitation in sepsis

Efficacy of Ulinastatin Combined with Continuous Renal Replacement Therapy in the Treatment of Sepsis Acute Kidney Injury and Its Effects on Systemic Inflammation, Immune Function and miRAN Expression

Multi-center clinical trial on the treatment of acute pancreatitis by ulinastatin

Safety of Different Doses of Ulinastatin Combined with Remifentanil in the Treatment of Severe Sepsis in ICU and Their effect on Survival Rate and Organ Function of Patients